药易购(300937) - 300937药易购投资者关系管理信息20250610

Group 1: Financial Performance - The company's net increase in cash and cash equivalents improved from -143 million in 2023 to 43 million in 2024, a total increase of 186 million [2] - Net cash flow from operating activities rose from -115 million in 2023 to 128 million in 2024, an increase of 243 million, attributed to better management of supplier prepayments and accounts payable [2] - Net cash flow from financing activities decreased from 107 million in 2023 to -35 million in 2024, primarily due to enhanced capital turnover and repayment of bank loans [2] - Net cash flow from investing activities improved from -135 million in 2023 to -50 million in 2024, with the previous year's outflow largely due to bank guarantee deposits [2] Group 2: Investment Strategy in Ethnic and Traditional Medicine - The company is leveraging policy support for ethnic medicine, as outlined in the Traditional Chinese Medicine Law, which includes the integration of ethnic medicines into the national healthcare system [3] - The company has secured exclusive sales rights for several ethnic medicines, including a partnership with Kashgar Kunlun Uyghur Pharmaceutical Co. for a unique rose oral liquid product [3] - The company is actively pursuing investments in traditional Chinese medicine (TCM) through equity cooperation and exclusive distribution agreements, such as a strategic partnership with Suzhou Yusen New Drug Development Co. for a TCM product [3] - Future strategies include deepening investments in ethnic and TCM industries through equity partnerships and exclusive operations to foster innovation and efficient development [3]